Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 04 March 2015 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) is increasingly paying attention to social media, and in particular Facebook, as companies use the social networking platform to market their products.
In at least six Warning Letters issued since October 2014, FDA has referenced promotional claims used to market products on Facebook.
FDA's letters provide evidence that the agency cares just as much about what a company says on its social media channels as on its website.
For example, in October 2014, FDA issued a Warning Letter to Vitalab, citing the company's Facebook posts which claimed its "Vit-Ra-Tox" products could be used to treat food poisoning, cholera, bacterial and parasitical infections, and heavy metals. Another Facebook post claimed a product would help the body to "repair broken bones."
None of these claims had been approved by FDA, the regulator wrote in its letter.
Similar claims were leveled against Florida-based NanoBiotech in February 2015. FDA said the company had been improperly marketing its NanobacTX and Urobac products since at least August 2013. In all, FDA cited eight Facebook posts by the company spanning 15 months.
Facebook posts weren't the only thing grabbing FDA's attention. Another online retailer was cited for including unapproved claims in the "About" section of its Facebook page that its products could help prevent cancer, treat infections and reduce inflammation.
Notably, the four Warning Letters citing Facebook sent in late February represents FDA's largest-ever batch of letters citing Facebook. The agency's previous record was in September 2014, when it sent three in the same week.
Despite the high volume, FDA's latest letters avoid some of its most controversial interpretations of social media policy. For example, in February 2013 FDA issued a Warning Letter to a company citing its "Like" of an unapproved claim posted to the company's Facebook "wall." FDA said the "like" represented an endorsement of the claim. A similar letter citing an improper Facebook "like" was sent by FDA in July 2014.
FDA has not cited a "liked" status in its Warning Letters since July 2014.
Tags: Facebook, FDA Regulation of Social Media, FDA Social Media, Warning Letter
Regulatory Focus newsletters
All the biggest regulatory news and happenings.